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Previewset al. (2014) examined the role of indi-
vidual CBS domains within the g subunit.
When g subunit residues Asp90 (site 1),
Asp245 (site 3), and Asp317 (site 4) were
individually exchanged with Ala, syner-
gistic activation induced by the combined
action of A-769662 and AMP was
severely blunted.
Collectively, Scott et al. (2014) report
how AMPK can be activated via a purely
allosteric mechanism, bypassing the
requirement of a subunit Thr172 and b
subunit Ser108 phosphorylation. These
findings are highly relevant for the devel-
opment of specific directly-acting AMPK
agonists and the future direction of
AMPK-based therapy in disease-focused
research. This study is also critical to our
understanding of how to target AMPK
pharmacologically, depending on the
cellular context (e.g., genetic loss of up-
stream kinase and expression of b1- and
b2-subunits). There have been two recent
reports evaluating the functional effects of
A-769662 in combination with AICAR or
indirect AMPK activators (metformin,
phenformin, oligomycin, and hypoxia)
acting via the elevation of cellular AMP
levels. Consistent with enhanced AMPK
activation by co-treatment, inhibition of
hepatic lipogenesis (Ducommun et al.,
2014) and activation of cardiac glucosetransport (Timmermans et al., 2014)
were greatly improved compared with
A-769662 alone. These results reinforce
the view that combinatorial treatments
would be of value to enhance AMPK acti-
vation. In addition, such treatments could
help to reduce the amount of drugs
administrated to patients and better
balance tolerability and efficacy. Future
research will have to elucidate the benefi-
cial effects of metformin in combination
with various AMPK activators targeting
the A-769662 binding site for patients
suffering with type 2 diabetes, insulin
resistance, cardiovascular diseases, and
also cancer.REFERENCES
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In this issue of Chemistry & Biology, Hari and colleagues show that conformation-selective ATP-competitive
kinase inhibitors have distinct noncatalytic effects on Erk2, including the ability to modulate protein-protein
interactions outside the ATP-binding site. These findings enhance our knowledge about the diverse array of
activities in which kinase inhibitors can target signaling pathways.Elucidating imatinib’s binding mode with
c-Abl prompted the development of
myriad kinase inhibitors that stabilize (or
bind to) the inactive DFG-out conforma-
tion (Figure 1A). It was originally believed
that the DFG-out conformation was non-
conserved across the kinome and there-fore explained the selectivity of imatinib.
However, recent studies have shown
that the inactive DFG-out conformation
is not unique and inhibitors that stabi-
lize this conformation are not inherently
more selective than inhibitors that bind
the active conformation.Although there aremanyDFG-out inhib-
itors (also known as type II kinase inhibi-
tors) known, only recently has there been
an appreciation that conformation-selec-
tive inhibitors, including DFG-out inhibi-
tors, can uniquely modulate noncatalytic
functions of kinases. The first reportª2014 Elsevier Ltd All rights reserved 569
Figure 1. Structural Depiction of Active versus DFG-out Kinase Conformations of c-Abl
and p38a
(A) Superimposed structures of c-Abl. The green-colored activation loop is DFG-in, active conformation
(PDB: 2GQG). The red-colored activation loop is DFG-out, inactive conformation (PDB: 1IEP).
(B) Superimposed structures of p38a. The green-colored activation loop is DFG-in, active conformation
(PDB: 1ZZL). The red-colored activation loop is DFG-out, inactive conformation (PDB: 2BAJ). In the stick
depiction is Phe-169 of the DFG motif and Thr-180, which is recognized by MKK6 in the active conforma-
tion. The distance Thr-180 moves in the active versus inactive conformation is 13.9 A˚.
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Previewsshowing differential activities between in-
hibitors that are compatible with an active
ATP-binding site conformation and DFG-
out inhibitorswas in 2005,whereinSullivan
and coworkers described the unique abil-
ity of DFG-out inhibitors to prevent phos-
phorylation of inhibitor-bound p38a by
MKK6 (Sullivan et al., 2005).More recently,
several groups have reported conforma-
tion-selective modulation of noncatalytic
kinase activity. These studies have yieldedFigure 2. Structural Depiction of aC-Helix in Ac
of Cdk2 and Erk2
(A) Superimposed structures of Cdk2 kinase domain in
cyclin A is bound to Cdk2, Cdk2 is in the active aC-heli
clarity, cyclin A is hidden. In the absence of cyclin A
(aC-helix, red; PDB: 1PW2).
(B) Superimposed structures of Erk2 bound to putative
to cyclin A (PDB: 1OKV). The L16 segment of Erk2 (da
(pink) occupies when bound to Cdk2. Both structural f
aC-helix in, active conformation.
570 Chemistry & Biology 21, May 22, 2014 ªa diverse array of kinases that are differen-
tially effected by conformation-selective
inhibitors, including the ability to modu-
late the ribonuclease activity of Ire1a
selectively with DFG-out inhibitors (Wang
et al., 2012) and the ability of conforma-
tion-selective kinase inhibitors to perturb
noncatalytic interactionsof c-Src (Krishna-
murty et al., 2013).
In this issue of Chemistry & Biology by
Hari et al. (2014), conformation-selectivetive versus aC-Helix out Inactive Structures
the presence and absence of bound cyclin A.When
x in conformation (aC-helix, green; PDB: 1OKV). For
, Cdk2 is in the inactive aC-helix out conformation
aC-helix out inhibitor (PDB: 4N4S) andCdk2 bound
rk red) occupies a similar binding side that cyclin A
eatures aid in ‘‘locking’’ the respective kinase in the
2014 Elsevier Ltd All rights reservedinhibitors of Erk2 are shown to have differ-
ential functions depending on the kinase
conformation stabilized. The study of
Erk2 is significant because, unlike most
previous examples, Erk2 does not have
regulatory domains, which is a common
site of noncatalytic activity. In addition, a
substantial number of noncatalytic func-
tions for the kinase domain of Erk2 have
been reported (Rodrı´guez and Crespo
2011). Using detailed biochemical and
cellular experiments, the authors show
that DFG-out inhibitors can uniquely
(compared to active-conformation inhibi-
tors) reduce Erk2 phosphorylation by
MEK2. In addition, the authors demon-
strate that targeting the inactive DFG-out
conformation modulated Erk20s ability to
allosterically activate DUSP6 phospha-
tase. Both active and DFG-out stabilizing
inhibitors are able to inhibit the catalytic
activity of Erk2, but only DFG-out stabiliz-
ing inhibitors have the allosteric effects on
Erk2. This hypothesis is due to the large
change in conformation of the kinase
activation loop (A-loop), which is a known
consequence of a kinase in the DFG-out
conformation. This hypothesis is consis-
tent with studies demonstrating that
MKK6 is unable to phosphorylate Thr-
180 on p38a when p38a is bound by
DFG-out inhibitors (Figure 1B).
A second inactive conformation that is
frequently found in both apo and ligand-
bound kinases is called the aC-helix out
conformation. Maly and coworkers have
previously shown that ATP-competitive
inhibitors of c-Src kinase that stabilize
c-Src in the aC-helix out conformation
(also referred to as the Src/Cdk-like inac-
tive conformation) lead to a closing of the
kinase that reduces accessibility to c-Src
SH3 domain (Krishnamurty et al., 2013).
This prior work demonstrates that, like
DFG-out inhibitors, compounds that
stabilize the aC-helix out conformation
can modulate noncatalytic activity of
kinases. In this report, Hari and col-
leagues identify a potent inhibitor of Erk2
that has structural features similar to
known aC-helix out inhibitors of c-Src.
Despite predicting that the Erk2 inhibitor
would stabilize the aC-helix out confor-
mation, no modulation of noncatalytic
activity was observed. Upon structural
analysis, the designed aC-helix out
inhibitor of Erk2 does not cause outward
rotation of the aC-helix, a classic feature
of this inactive conformation (Figure 2).
Chemistry & Biology
PreviewsThe inability of Erk2 to adopt the
canonical aC-helix out conformation is
likely due to the presence of a unique
insertion domain found in MAPKs (L16
segment) that can prevent movement of
the aC-helix. The L16 segment is found
to occupy similar space as cyclin A bind-
ing of Cdk2, a binding event that prevents
Cdk2 from adopting the aC-helix out
conformation (Schulze-Gahmen et al.,
1996) (Figure 2). Similar to the ability of
Syk kinase to bind DFG-out ligands in
an active conformation (e.g., imatinib),
these results highlight the importance of
structurally characterizing conformation-
ally selective inhibitors with their target
kinase.
This work, together with previous re-
ports, highlights the large range of allo-steric effects that some kinase inhibitors
can modulate. These allosteric effects
are neglected in most reports of kinase in-
hibitor development; however, the ability
of select inhibitors to modulate noncata-
lytic function can have profound pharma-
cological consequences when applying
these kinase inhibitors to cellular systems.
A picture is emerging that DFG-out inhib-
itors (and some aC-helix out inhibitors)
have the ability to disrupt noncatalytic
kinase function, while active conforma-
tion inhibitors do not. These new findings
increase the complexity of predicting
outcomes for kinase inhibitors, but,
nevertheless, studies similar to this work
are essential to reveal the vast array of ac-
tivities that can emerge from kinase
inhibitors.Chemistry & Biology 21, May 22, 2014REFERENCES
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In this issue of Chemistry & Biology, Kirkpatrick and Viollier describe a new twist in the relationship between
bacterial cell development and antibiotic resistance. They reveal that TipN, which orchestrates development
at cell poles, is required to tolerate induced expression of an antibiotic efflux pump.The utility of antibiotics as therapeutics
lies in their selective inhibition of prokary-
otic pathways. With the increasing preva-
lence of antibiotic resistance, identifica-
tion of novel prokaryotic targets for the
development of new classes of antibiotics
is essential. The article by Kirkpatrick and
Viollier (2014) in this issue of Chemistry &
Biology suggests that proteins involved
in bacterial cell polarity determination
could serve as targets for combination
therapeutic agents that enhance the effi-
cacy of current antibiotics, even in strains
that are resistant. The model a-proteo-
bacterium Caulobacter crescentus is
resistant to the quinolone antibiotic Nali-
dixic acid (Nal) owing to a polymorphism
in DNA gyrase, the target of Nal. Kirkpa-
trick and Viollier (2014) show that disrup-tion of a cell polarity factor, TipN, which
marks the new cell pole and the site of
flagellar assembly (Huitema et al., 2006;
Lam et al., 2006), sensitizes Caulobacter
to Nal and restores antibiotic toxicity by
a novel mechanism.
Bacterial resistance to antibiotics
typically arises by one of three mecha-
nisms: (1) alteration of the drug target
such that the drug can no longer bind,
(2) modification or degradation of the
drug itself, or (3) acquisition or enhanced
expression of efflux pumps that expel the
drug from the cell. The first two mecha-
nisms can confer resistance to one or a
few very closely related antibiotics. Efflux
systems, on the other hand, can trans-
port a large repertoire of chemically
unrelated molecules. Thus induction ofsuch systems presents a mechanism
by which bacteria acquire resistance
to broad groups of antibiotics (Putman
et al., 2000).
The resistance-nodulation-division
(RND) transporters represent an impor-
tant family of efflux systems that are
capable of transferring molecules directly
from the cytoplasm or the periplasm to
the exterior of the cell. These tripartite
systems, typified by AcrAB-TolC, have
components in the inner membrane
(AcrB), the periplasm (AcrA), and the outer
membrane (TolC) that together form a
continuous vehicle to export molecules
from the cell (Fernando and Kumar,
2013). Expression of these systems is
often regulated by a TetR-like transcrip-
tional repressor that controls transcriptionª2014 Elsevier Ltd All rights reserved 571
